Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Brian T. Kalet"'
Autor:
Brian T Kalet, Sara R Anglin, Anne Handschy, Liza E O'Donoghue, Charles Halsey, Laura Chubb, Christopher Korch, Dawn L Duval
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68815 (2013)
The purpose of this study was to explore the role of transcription factor Ets1 in estrogen receptor α (ERα)-positive breast cancer progression. We expressed human Ets1 or empty vector in four human ERα-positive breast cancer cell lines and observe
Externí odkaz:
https://doaj.org/article/4f6f72807f9247d2a28ac243601ae92b
Publikováno v:
The FASEB Journal. 33
Publikováno v:
Molecular Cancer Therapeutics. 3:1593-1604
We have reported the synthesis and biological evaluation of a prodrug to a doxorubicin active metabolite. Under physiologic conditions, release of the active metabolite, a conjugate of doxorubicin with formaldehyde, occurs with a half-life of 1 hour.
Autor:
Tad H, Koch, Benjamin L, Barthel, Brian T, Kalet, Daniel L, Rudnicki, Glen C, Post, David J, Burkhart
Publikováno v:
Topics in current chemistry. 283
The sequence of research leading to a proposal for anthracycline cross-linking of DNA is presented.The clinical anthracycline antitumor drugs are anthraquinones, and as such are redox active. Their redoxchemistry leads to induction of oxidative stres
Autor:
Sara R. Anglin, Liza E. O’Donoghue, Charles H. C. Halsey, Brian T. Kalet, Laura S. Chubb, Dawn L. Duval, Anne V. Handschy, Christopher Korch
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 7, p e68815 (2013)
PLoS ONE, Vol 8, Iss 7, p e68815 (2013)
The purpose of this study was to explore the role of transcription factor Ets1 in estrogen receptor α (ERα)-positive breast cancer progression. We expressed human Ets1 or empty vector in four human ERα-positive breast cancer cell lines and observe
The mechanism of doxorubicin is compared with that of doxazolidine, a doxorubicin-formaldehyde conjugate. The IC(50) for growth inhibition of 67 human cancer cell lines, but not cardiomyocytes, is 32-fold lower with doxazolidine than with doxorubicin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bb0c4b4fa6dcaa3fa0d098c7021dd1
https://europepmc.org/articles/PMC2919335/
https://europepmc.org/articles/PMC2919335/
Autor:
Tad H. Koch, David J. Burkhart, Brian T. Kalet, Daniel L. Rudnicki, Benjamin L. Barthel, Glen C. Post
Publikováno v:
Topics in Current Chemistry ISBN: 9783540758129
The sequence of research leading to a proposal for anthracycline cross-linking of DNA is presented.The clinical anthracycline antitumor drugs are anthraquinones, and as such are redox active. Their redoxchemistry leads to induction of oxidative stres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c7433d267ad4d12dbb12328b9055c5a
https://doi.org/10.1007/128_2007_4
https://doi.org/10.1007/128_2007_4
Autor:
Benjamin L. Barthel, Jordan W. Nafie, Brian T. Kalet, David J. Burkhart, Glen C. Post, Richard K. Shoemaker, Tad H. Koch
The synthesis and tumor cell growth inhibition by doxazolidine carbamate prodrugs are reported. The carbamates were designed for selective hydrolysis by one or more human carboxylesterases to release doxazolidine (Doxaz), the formaldehyde-oxazolidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9974ccc15be86f1e81221edce8d585a8
https://europepmc.org/articles/PMC2569826/
https://europepmc.org/articles/PMC2569826/
Publikováno v:
Molecular Cancer Research. 12:A23-A23
Osteosarcoma (OSA) is the most common bone tumor in children. Dose intensive therapies have resulted in survival rates of 75%, however for patients with metastasis at diagnosis, the survival rate is only 20%, indicating the need for improved therapeu
Publikováno v:
Molecular cancer therapeutics. 3(12)
We have reported the synthesis and biological evaluation of a prodrug to a doxorubicin active metabolite. Under physiologic conditions, release of the active metabolite, a conjugate of doxorubicin with formaldehyde, occurs with a half-life of 1 hour.